ClinicalTrials.gg
CompletedNCT05147337Updated Sep 9, 2022

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

A Phase 1 interventional study of E2511 and Placebo in Healthy Volunteers, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-09.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the safety, tolerability, and plasma pharmacokinetic (PK) of E2511 following multiple oral doses in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • E2511
  • Healthy Participants
  • Elderly Participants
03

In context

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Non-smoking, male, or female, non-Japanese participants age >=18 years and \<55 years old (Cohorts 1 to 4) or age >=55 years and \<=85 years old (Cohort 8); or Japanese participants age >=20 years and \<55 years old (Cohorts 5 to 7) at the time of
  2. Japanese participants must also satisfy the following requirements:

    • Must have been born in Japan of Japanese parents and Japanese grandparents
    • Must have lived no more than 5 years outside of Japan
    • Must not have changed their lifestyle or habits, including diet, while living outside of Japan
  3. Weight of at least 50 kilogram (kg) and (BMI) >=18 and \<30 kilogram per square meter (kg/m\^2) (Cohorts 1 to 7) or BMI >=18 and \<32 kg/m\^2 (Cohort 8) at Screening

Exclusion criteria

Exclusion Criteria:

  1. Females who are breastfeeding or pregnant at Screening or Baseline
  2. Females of who:

    • Within 28 days before study entry, did not use a highly effective method of
    • Do not agree to use a highly effective method of contraception throughout the entire study period and for 28 days after study drug discontinuation.
  3. illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing
  4. Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; example, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism
  5. Evidence of disease within 4 weeks before dosing related to chronic headaches, migraines, joint pain, or other disorders or disease resulting in chronic or intermittent pain
  6. Any personal or family history of seizures (including febrile seizures) or diagnosis of epilepsy or episode of unexplained loss of consciousness
  7. Any history of neurological or other medical conditions which in the opinion of the investigator has the potential to reduce seizure threshold
  8. Any history of gastrointestinal surgery that may affect PK profiles of E2511, example, hepatectomy, nephrectomy, digestive organ resection at Screening
  9. Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, finding, or laboratory test results that require medical treatment at Screening or Baseline
  10. A prolonged /QT interval corrected for heart rate (QTc) interval or a prolonged QT/QTc interval (QT interval corrected for heart rate using Fridericia's formula [QTcF] greater than [>] 450 milliseconds [ms]). A history of risk factors for torsade de pointes
  11. HR \<50 or more than 100 beats per minute at Screening or Baseline (Cohorts 1 through 7); or HR \<55 or more than 100 beats per minute at Screening or Baseline (Cohort 8) NOTE: At Baseline, HR must meet the above criteria on 3 assessments (each separated by 15 minutes) to ensure eligibility
  12. Left bundle branch block
  13. History of myocardial infarction or active ischemic heart disease
  14. History of clinically significant arrhythmia or uncontrolled arrhythmia
  15. Any lifetime history of suicidal ideation or any lifetime history of suicidal behavior as indicated by the C-SSRS
  16. Any lifetime history of psychiatric disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Cohort 1: E2511 10 mg or Placebo

    Non-Japanese adult (greater than or equal to \[\>=\] 18 years and less than \[\<\] 55 years old) participants will receive 10 milligram (mg) E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.

    Drug: E2511 · Drug: Placebo

  • Experimental
    Cohort 2: E2511 20 mg or Placebo

    Non-Japanese adult participants will receive 20 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.

    Drug: E2511 · Drug: Placebo

  • Experimental
    Cohort 3: E2511 40 mg or Placebo

    Non-Japanese adult participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.

    Drug: E2511 · Drug: Placebo

  • Experimental
    Cohort 4: E2511 80 mg or Placebo

    Non-Japanese adult participants will receive 80 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.

    Drug: E2511 · Drug: Placebo

  • Experimental
    Cohort 5: E2511 20 mg or Placebo

    Japanese adult (\>=20 years and \<55 years old) participants will receive 20 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.

    Drug: E2511 · Drug: Placebo

  • Experimental
    Cohort 6: E2511 40 mg or Placebo

    Japanese adult participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.

    Drug: E2511 · Drug: Placebo

  • Experimental
    Cohort 7: E2511 80 mg or Placebo

    Japanese adult participants will receive 80 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.

    Drug: E2511 · Drug: Placebo

  • Experimental
    Cohort 8: E2511 40 mg or Placebo

    Non-Japanese older (\>=55 years and less than or equal to \[\<=\] 85 years old) participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.

    Drug: E2511 · Drug: Placebo

Interventions

  • DrugE2511

    E2511 tablets.

  • DrugPlacebo

    E2511 matched placebo tablets.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: From Screening up to 14 days after the last dose of study drug (up to 56 days)

  2. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: From Screening up to 14 days after the last dose of study drug (up to 56 days)

  3. Number of Participants With Clinically Significant Abnormal Laboratory Values

    Time frame: From Screening up to 14 days after the last dose of study drug (up to 56 days)

  4. Number of Participants With Clinically Significant Abnormal Vital Signs Values

    Time frame: From Screening up to 14 days after the last dose of study drug (up to 56 days)

  5. Number of Participants With Clinically Significant Abnormal Electrocardiograms (ECGs) Findings

    Time frame: From Screening up to 14 days after the last dose of study drug (up to 56 days)

  6. Number of Participants With Clinically Significant Abnormal Ambulatory Blood Pressure

    Time frame: From Screening up to 14 days after the last dose of study drug (up to 56 days)

  7. Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-suicide Severity Rating Scale (C-SSRS)

    The C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \[C-CASA\]) is an interview-based rating scale to systematically assess any suicidality, suicidal behavior, or suicidal ideation. Any suicidality is emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior is indicated when response is "yes" for any these questions- actual attempt to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation is indicated when response is "yes" for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide.

    Time frame: From Screening up to 14 days after the last dose of study drug (up to 56 days)

  8. Number of Participants With Clinically Significant Abnormal Physical Examination Findings

    Time frame: From Screening up to 14 days after the last dose of study drug (up to 56 days)

  9. Number of Participants With Clinically Significant Abnormal Neurological Examination Findings

    Time frame: From Screening up to 14 days after the last dose of study drug (up to 56 days)

  10. Number of Participants With Clinically Significant Abnormal Electroencephalogram (EEG) Findings

    Time frame: From Screening up to 14 days after the last dose of study drug (up to 56 days)

  11. Cmax: Maximum Observed Plasma Concentration for E2511

    Time frame: Day 1: pre-dose up to 24 hours post-dose

  12. Css,max: Maximum Observed Plasma Concentration at Steady State for E2511

    Time frame: Day 14: pre-dose up to 24 hours post-dose

  13. tmax: Time to Reach Maximum Observed Plasma Concentration (Cmax) for E2511

    Time frame: Day 1: pre-dose up to 24 hours post-dose

  14. tss,max: Time to Reach Maximum Observed Plasma Concentration (Cmax) at Steady State for E2511

    Time frame: Day 14: pre-dose up to 24 hours post-dose

  15. Css,av: Average Steady State Plasma Concentration for E2511

    Time frame: Day 14: pre-dose up to 24 hours post-dose

  16. AUC(0-t): Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration for E2511

    Time frame: Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose

  17. AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time Zero to Infinite for E2511

    Time frame: Day 1: pre-dose up to 24 hours post-dose

  18. AUC(0-24h): Area Under the Plasma Concentration-time Curve From Time Zero to 24 hours Post-dose for E2511

    Time frame: Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose

  19. t1/2: Terminal Elimination Phase Half-life for E2511

    Time frame: Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose

  20. PTF: Peak-trough Fluctuation for E2511

    Time frame: Day 14: pre-dose up to 24 hours post-dose

  21. CL/F: Apparent Total Clearance for E2511

    Time frame: Day 1: pre-dose up to 24 hours post-dose

  22. CLss/F: Apparent Total Clearance at Steady State for E2511

    Time frame: Day 14: pre-dose up to 24 hours post-dose

  23. Vz/F: Apparent Volume of Distribution at Terminal Phase for E2511

    Time frame: Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose

  24. Rac: Accumulation Ratio for E2511 Based on Cmax and AUC

    Time frame: Day 14: pre-dose up to 24 hours post-dose

  25. Rss: Accumulation Ratio for E2511 Based on Time and Concentration

    Time frame: Day 14: pre-dose up to 24 hours post-dose

Secondary outcomes

  1. Change From Baseline in the Concentration of Acetylcholine (ACh) in Cerebrospinal Fluid (CSF)

    Time frame: Baseline, Day 13

  2. Change From Baseline in Heart Rate (HR)

    Time frame: Baseline up to Day 15

  3. Change From Baseline in PR Interval of the ECG (PR), QRS Interval of the ECG (QRS), and QT Interval Corrected for Heart Rate (QTc) of the ECG

    Time frame: Baseline up to Day 15

  4. Placebo Corrected Change From Baseline in HR

    Time frame: Baseline up to Day 15

  5. Placebo Corrected Change From Baseline in PR, QRS, and QTc Interval

    Time frame: Baseline up to Day 15

  6. Number of Participants With Categorical Outliers for HR, PR, QRS and QTc Interval

    Time frame: Baseline up to Day 15

  7. Number of Participants With Treatment-emergent T-wave and U-wave abnormalities

    Time frame: Baseline up to Day 15

  8. Mean Change From Baseline in 24-hours Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) up to Day 15

    The blood pressure (BP) will be evaluated by Ambulatory Blood Pressure Monitoring (ABPM) for all participants based on the measurement of BP recordings after every 24 hours.

    Time frame: Up to Day 15

  9. Mean Change From Baseline in Day-time, Night-time, and Hourly SBP and DBP

    Time frame: Baseline up to Day 15

  10. Mean Change From Baseline in Day-time, Night-time, and Hourly HR

    Time frame: Baseline up to Day 15

  11. Mean Change From Baseline in Day-time, Night-time, and Hourly Mean Arterial Pressure (MAP) and Pulse Pressure (PP)

    Time frame: Baseline up to Day 15

  12. Placebo Corrected Mean Change From Baseline in 24-hours SBP and DBP up to Day 15

    The BP will be evaluated by ABPM for all participants based on the measurement of BP recordings after every 24 hours.

    Time frame: Up to Day 15

  13. Placebo Corrected Mean Change From Baseline in Day-time, Night-time, and Hourly SBP and DBP

    Time frame: Baseline up to Day 15

  14. Placebo Corrected Mean Change From Baseline in Day-time, Night-time, and Hourly HR

    Time frame: Baseline up to Day 15

  15. Placebo Corrected Mean Change From Baseline in Day-time, Night-time, and Hourly MAP and PP

    Time frame: Baseline up to Day 15

  16. Number of Participants With Categorical Outliers for SBP and DBP

    Time frame: Baseline up to Day 15

  17. Geometric Mean Ratio of Cmax Between the Healthy Japanese and Non-japanese Participants for E2511

    Time frame: Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose

  18. Geometric Mean Ratio of AUC Between the Healthy Japanese and Non-japanese Participants for E2511

    Time frame: Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose

  19. Geometric Mean Ratio of Cmax Between the Younger Non-japanese (>=18 and <55 years) and older Non-japanese (>=55 to <=85 years) Participants for E2511

    Time frame: Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose

  20. Geometric Mean Ratio of AUC Between the Younger Non-japanese (>=18 and <55 years) and older Non-japanese (>=55 to <=85 years) Participants for E2511

    Time frame: Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose

  21. Geometric Mean Ratio Between the Non-japanese (>=18 and <55 years) and Elderly Non-japanese (>=65 to <=85 years) Participants for E2511

    Time frame: Day 1: pre-dose up to 24 hours post-dose; Day 14: pre-dose up to 24 hours post-dose

07

Study locations

1 site
  • California Clinical Trials Medical Group
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Aug 2022, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2021
First posted
Dec 7, 2021
StartActual
Dec 1, 2021
Primary completionActual
Aug 18, 2022
CompletionActual
Aug 18, 2022
Last update
Sep 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05147337
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Dec 7, 2021
Start date
Dec 1, 2021
Primary completion
Aug 18, 2022
Completion
Aug 18, 2022
Last update
Sep 9, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: E2511

Start the discussion